Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
about
Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.Transcriptome Analysis of Canine Cutaneous Melanoma and Melanocytoma Reveals a Modulation of Genes Regulating Extracellular Matrix Metabolism and Cell Cycle.Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas.
P2860
Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Synergistic targeted inhibitio ...... el for human mucosal melanoma.
@en
Synergistic targeted inhibitio ...... el for human mucosal melanoma.
@nl
type
label
Synergistic targeted inhibitio ...... el for human mucosal melanoma.
@en
Synergistic targeted inhibitio ...... el for human mucosal melanoma.
@nl
prefLabel
Synergistic targeted inhibitio ...... el for human mucosal melanoma.
@en
Synergistic targeted inhibitio ...... el for human mucosal melanoma.
@nl
P2093
P2860
P356
P1476
Synergistic targeted inhibitio ...... del for human mucosal melanoma
@en
P2093
Amit Adhikari
Bih-Rong Wei
Charles H C Halsey
Cody J Peer
Glenn Merlino
Jennifer E Dwyer
R Mark Simpson
Rajaa El Meskini
Serguei Kozlov
Shelley B Hoover
P2860
P304
P356
10.1111/PCMR.12512
P577
2016-09-22T00:00:00Z